SG11201900027XA - Anti-o2 antibodies and uses thereof - Google Patents

Anti-o2 antibodies and uses thereof

Info

Publication number
SG11201900027XA
SG11201900027XA SG11201900027XA SG11201900027XA SG11201900027XA SG 11201900027X A SG11201900027X A SG 11201900027XA SG 11201900027X A SG11201900027X A SG 11201900027XA SG 11201900027X A SG11201900027X A SG 11201900027XA SG 11201900027X A SG11201900027X A SG 11201900027XA
Authority
SG
Singapore
Prior art keywords
medlmmune
gaithersburg
llc
way
klebsiella
Prior art date
Application number
SG11201900027XA
Inventor
Qun Wang
Charles Stover
Meghan Pennini
Xiaodong Xiao
Davide Corti
Elisabetta Cameroni
Martina Beltramello
Gilad Kaplan
Anna Demarco
Original Assignee
Medimmune Llc
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Humabs Biomed Sa filed Critical Medimmune Llc
Publication of SG11201900027XA publication Critical patent/SG11201900027XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111101111011101 HRH 110 1 001111010M 0111110111111011110111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/027124 Al 08 February 2018 (08.02.2018) WIP0 I PCT (51) International Patent Classification: Med SA, Mirasole 1, CH-6500 Bellinzona (CH). BEL- A 61K 39/02 (2006.01) A61K 39/40 (2006.01) TRAMELLO, Martina; Humabs BioMed SA, Mirasole A61K 39/108 (2006.01) A61K 31/715 (2006.01) 1, CH-6500 Bellinzona (CH). KAPLAN, Gilad; Medlm- A61K 39/395 (2006.01) Cl 2P 21/08 (2006.01) mune, Llc, One Medlmmune Way, Gaithersburg, MD (21) International Application Number: 20878 (US). DEMARCO, Anna; Humabs BioMed SA, Mirasole 1, Bellinzona CH-6500 (CH). PCT/US2017/045480 (22) International Filing Date: (74) Agent: MARTIN, Cynthia, Lan et al.; Medlmmune, LLC, 04 August 2017 (04.08.2017) One Medimmune Way, Gaithersburg, MD 20878 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/371,402 05 August 2016 (05.08.2016) US DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicants: MEDIMMUNE, LLC [US/US]; One Medlm- KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, mune Way, Gaithersburg, MD 20878 (US). HUMABS, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, BIOMED, SA [CH/CH]; Mirasole 1, CH (CH). -6500 Bellinzona OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (72) Inventors: WANG, Qun; Medlmmune, Llc, One Medlm- mune Way, Gaithersburg, MD 20878 (US). STOVER, (84) Designated States (unless otherwise indicated, for every Charles, K.; Medlmmune, Llc, One Medlmmune Way, kind of regional protection available): ARIPO (BW, GH, = Gaithersburg, MD 20878 (US). PENNINI, Meghan; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Medlmmune, Llc, One Medlmmune Way, Gaithersburg, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = _ MD 20878 (US). XIAO, Xiaodong; Medlmmune, Llc, One TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — Medlmmune Way, Gaithersburg, MD 20878 (US). CORTI, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Davide; Humabs BioMed SA, Mirasole 1, CH-6500 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Bellinzona (CH). CAMERONI, Elisabetta; Humabs Bio- = (54) Title: ANTI-02 ANTIBODIES AND USES THEREOF = = Fla - IA = = 0-serotype D-Galactan determining = antigen al cts H D-Galactan I , , KPDI ,, .., ., 4 = = = = = CD LPS-0 _ c - Es antigen co (73 7 c) - L - as r, co • To- 57) ) c n r Wz//4 V — = — Il .4 core , core A 0-antigen 1 2 3 4 5 7 12 ei N 01 02 serotype 1-1 IN (57) : The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically 0 \" bind ---- from a lethal to Klebsiellapneumoniae 02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) GO , 1 or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneu- moniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject. ei C [Continued on next page] WO 2018/027124 Al MIDEDIMOMMIDIIMERIONMOIDEEDHOMEMOVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) he Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201900027XA 2016-08-05 2017-08-04 Anti-o2 antibodies and uses thereof SG11201900027XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371402P 2016-08-05 2016-08-05
PCT/US2017/045480 WO2018027124A1 (en) 2016-08-05 2017-08-04 Anti-o2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900027XA true SG11201900027XA (en) 2019-02-27

Family

ID=61073270

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900027XA SG11201900027XA (en) 2016-08-05 2017-08-04 Anti-o2 antibodies and uses thereof

Country Status (12)

Country Link
US (2) US11447542B2 (en)
EP (1) EP3496748A4 (en)
JP (1) JP7161266B2 (en)
KR (1) KR20190077306A (en)
CN (1) CN109689090B (en)
AU (1) AU2017306709A1 (en)
BR (1) BR112019002039A2 (en)
CA (1) CA3031735A1 (en)
EA (1) EA201990222A1 (en)
IL (1) IL264417A (en)
SG (1) SG11201900027XA (en)
WO (1) WO2018027124A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689090B (en) 2016-08-05 2023-12-26 免疫医疗有限责任公司 anti-O2 antibodies and uses thereof
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
WO2021186398A1 (en) * 2020-03-19 2021-09-23 Medimmune Limited Anti-klebsiella pneumoniae antibodies and uses thereof
WO2022015668A1 (en) * 2020-07-15 2022-01-20 Regents Of The University Of Minnesota SARS-CoV-2 NANOBODIES AND METHODS OF USE THEREOF
CN116829179A (en) * 2021-12-06 2023-09-29 北京三诺佳邑生物技术有限责任公司 Bispecific antibodies and compositions that specifically bind Klebsiella pneumoniae O2 antigen and O1 antigen

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
ES2129029T5 (en) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. DIRECT IMMUNOSTIMULATION WITH BISPECIFIC REAGENTS.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69214709T2 (en) 1991-04-26 1997-02-20 Surface Active Ltd New antibodies and methods of using them
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ544751A (en) 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
UA94060C2 (en) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Monoclonal antibodies that specifically binds alk-1
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses
CN102791285A (en) 2009-12-06 2012-11-21 比奥根艾迪克依蒙菲利亚公司 Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
MX2013000301A (en) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Chimeric clotting factors.
CN104169298B (en) 2012-03-08 2018-04-20 扬森疫苗与预防公司 It can combine and neutralize mankind's binding molecule of Type B influenza virus and application thereof
US9815820B2 (en) * 2012-10-05 2017-11-14 Kadmon Corporation, Llc Rho kinase inhibitors
PL404229A1 (en) * 2013-06-06 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by Gram-negative bacteria
CN106413750B (en) 2014-05-16 2022-04-29 免疫医疗有限责任公司 Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties
EP3259287A1 (en) 2015-02-17 2017-12-27 ARSANIS Biosciences GmbH Antibodies targeting a galactan-based o-antigen of k. pneumoniae
US20170073397A1 (en) 2015-08-24 2017-03-16 Medimmune, Llc MrkA Polypeptides, Antibodies, and Uses Thereof
EP3362474A1 (en) 2015-10-16 2018-08-22 ARSANIS Biosciences GmbH Bactericidal monoclonal antibody targeting klebsiella pneumoniae
CN109689090B (en) 2016-08-05 2023-12-26 免疫医疗有限责任公司 anti-O2 antibodies and uses thereof
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof

Also Published As

Publication number Publication date
BR112019002039A2 (en) 2019-05-07
CN109689090A (en) 2019-04-26
AU2017306709A1 (en) 2019-03-14
CA3031735A1 (en) 2018-02-08
US20230079661A1 (en) 2023-03-16
WO2018027124A8 (en) 2019-01-31
EA201990222A1 (en) 2019-07-31
IL264417A (en) 2019-02-28
JP7161266B2 (en) 2022-10-26
KR20190077306A (en) 2019-07-03
EP3496748A1 (en) 2019-06-19
EP3496748A4 (en) 2020-01-15
US20210238263A1 (en) 2021-08-05
JP2019534682A (en) 2019-12-05
CN109689090B (en) 2023-12-26
US11447542B2 (en) 2022-09-20
WO2018027124A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
SG11201900027XA (en) Anti-o2 antibodies and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201408459VA (en) Purification of virus like particles
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201805001UA (en) Method of treating influenza a
SG11201903063UA (en) Anti-o1 antibodies and uses thereof
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF